MedTrace Logo

rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia

NCT07653581 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-06-17

No results posted yet for this study

Summary

This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.

Conditions

  • Lower-risk Myelodysplastic Syndromes

Interventions

DRUG

rhTPO

rhTPO 300U/kg/d, subcutaneous injection, once a month for 14 consecutive days

DRUG

Cyclosporine (CsA)

CsA 3-5mg/kg/d

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-12-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07653581 on ClinicalTrials.gov